Ascendiant Capital Starts PhotoMedex (PHMD) at Buy; Market Growing; Attractive Valuation
Tweet Send to a FriendGet Alerts PHMD Hot Sheet
Price: $16.30 -0.85%
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade PHMD Now!
Ascendiant Capital initiates coverage on PhotoMedex (NASDAQ: PHMD) with a Buy. PT $18.50.
Analyst, Keay Nakae, said, "We believe that the December 2011 merger with the privately held Radiancy, has resulted in PhotoMedex becoming a much stronger company. The former PhotoMedex struggled to gain traction with its XTRAC laser therapy, used to treat inflammatory skin disease, and therefore struggled to achieve profitability. Thus, PHMD was an underperforming stock. The new PhotoMedex is now on track to generate over $150 MM in annual revenue, is solidly profitable, has essentially no debt, and is capable of generating meaningful free cash flow. We believe that the Company is well positioned to achieve faster revenue growth than its competitors and thus represents one of the more attractive investments in this segment."
For an analyst ratings summary and ratings history on PhotoMedex click here. For more ratings news on PhotoMedex click here.
Shares of PhotoMedex closed at $16.34 yesterday, with a 52 week range of $8.49-$16.81.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Keay Nakae, said, "We believe that the December 2011 merger with the privately held Radiancy, has resulted in PhotoMedex becoming a much stronger company. The former PhotoMedex struggled to gain traction with its XTRAC laser therapy, used to treat inflammatory skin disease, and therefore struggled to achieve profitability. Thus, PHMD was an underperforming stock. The new PhotoMedex is now on track to generate over $150 MM in annual revenue, is solidly profitable, has essentially no debt, and is capable of generating meaningful free cash flow. We believe that the Company is well positioned to achieve faster revenue growth than its competitors and thus represents one of the more attractive investments in this segment."
For an analyst ratings summary and ratings history on PhotoMedex click here. For more ratings news on PhotoMedex click here.
Shares of PhotoMedex closed at $16.34 yesterday, with a 52 week range of $8.49-$16.81.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Michael Kors (KORS) Under-Appreciated; Canaccord Genuity Starts at Buy
- BMO Capital Starts Pepsico (PEP) at Outperform
- BMO Capital Starts Coca-Cola (KO) at Market Perform
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
